The GS-7977/ribavirin oral regimen has failed miserably for the treatment of those genotype 1 hepatitis C patients that had previously failed treatment with interferon/ribavirin ("null responders"). The failure rate appears to be close to 100% and this was unexpected. The great results seen with GS-7977 in past studies were achieved when it was paired with both ribavirin and interferon. Apparently, GS-7977 is heavily dependent upon interferon to eradicate the hep C virus. It will be interesting to see how GS-7977/ribavirin performs in treatment-naive genotype 1 hep C patients. The odds of failure in this treatment-naive genotype 1 hep C went way up when it was announced that GS-7977 failed in null responders.